Dr. Blaine H. Mckee Ph.D. serves as Independent Director of the Company. Dr. McKee has served as a member of our Board since January 11, 2019. Dr. McKee has 25 years of experience in building biotechnology companies and has extensive strategic, transactional, and market access expertise. Dr. McKee is currently President and CEO TrisaQ, Inc., a Series A, venture capital -backed biopharmaceutical company targeting renal diseases. Prior to TrisaQ, Dr. McKee served as Executive Vice President and Chief Business Officer at ImmunoGen, Inc. from April 2018 to December 2019. Prior to joining ImmunoGen, Dr. McKee served in various executive capacities at Shire PLC, a pharmaceutical company, from 2014 to 2018, including as Senior Vice President, Head of Corporate Development, from 2016 to 2018, and as Senior Vice President, Head of Transactions, from 2014 to 2016. Prior to joining Shire PLC, from 2011 to 2014, Dr. McKee was Executive Vice President and Chief Business Officer at 480 Biomedical, a venture capital-backed medical device company. Prior to that he served for 15 years at Genzyme Corporation, a biopharmaceutical company, most recently serving as Senior Vice President of Strategic Development for the Oncology, Transplant, and Multiple Sclerosis divisions. Dr. McKee served on the board of the New York Pharma Forum from 2007 to 2011 and 2014 to 2019. He also served on the Board of BioStage, Inc from 2016 to 2018 and ArmaGen from 2015 to 2017. He received a Bachelor of Science in Chemistry from Colorado State University, a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology (MIT), and an MBA in Finance from the MIT Sloan School of Management.
As the Independent Director of VBI Vaccines, the total compensation of Blaine Mckee at VBI Vaccines is $470,250. There are 7 executives at VBI Vaccines getting paid more, with Jeffrey Baxter having the highest compensation of $1,379,630.
Blaine Mckee is 55, he's been the Independent Director of VBI Vaccines since 2019. There are 12 older and 7 younger executives at VBI Vaccines. The oldest executive at VBI Vaccines Inc. is Michel Wilde, 70, who is the Independent Director.
Blaine's mailing address filed with the SEC is C/O VBI VACCINES INC.,, 160 SECOND STREET, FLOOR 3, CAMBRIDGE, MA, 02142.
Over the last 8 years, insiders at VBI Vaccines have traded over $18,633,012 worth of VBI Vaccines stock and bought 55,142,222 units worth $66,770,591 . The most active insiders traders include Advisors Llcperceptive Life..., Tomer Kariv oraz Steven D Rubin. On average, VBI Vaccines executives and independent directors trade stock every 62 days with the average trade being worth of $130,457. The most recent stock trade was executed by Steven Gillis on 10 July 2023, trading 609,090 units of VBIV stock currently worth $1,004,999.
vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.
VBI Vaccines executives and other stock owners filed with the SEC include: